Abstract
Summary: To initiate an investigation into the biochemistry and mechanism of group B β-hemolytic Streptococcus virulence, bacterial cultures grown in suspension were centrifuged, and the bacteria and media were subjected to extensive fractionation. Each fraction was assayed for physiologic activity by repeated intravenous infusion into adult unanesthetized sheep. Pulmonary artery pressure, arterial Po2, and rectal temperature were monitored. The media fraction, but not the bacteria, contained a component (molecular weight, 2 X 106) composed of 84% carbohydrate and 16% protein with physiological activity. Two mg quantities, when infused, caused the pulmonary artery pressure to increase 100%, Po2 to decrease by 20% and chills and fever. The active component could be degraded by hot phenol-water extraction into a pure polysaccharide (molecular weight, 200,000). This lower molecular weight polysaccharide retained the identical physiologic properties when infused in the sheep. The degraded component precipitated with group B-specific antiserum.
This study demonstrates that, in the sheep, a pure polysaccharide is the physiologically active part of a high-molecular-weight toxin synthesized by group B β-hemolytic Streptococcus type III and that this component has a different carbohydrate composition from the group B capsular antigen.
Speculation: The clinical syndrome associated with group B β-hemolytic Streptococci in early onset disease is caused by the interactions of an extracellular bacterial component and a specific target tissue in the infected infant.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hellerqvist, C., Rojas, J., Green, R. et al. Studies on Group B β-Hemolytic Streptococcus. I. Isolation and Partial Characterization of an Extracellular Toxin. Pediatr Res 15, 892–898 (1981). https://doi.org/10.1203/00006450-198106000-00002
Issue Date:
DOI: https://doi.org/10.1203/00006450-198106000-00002
Keywords
This article is cited by
-
Group B Streptococcus, phospholipids and pulmonary hypertension
Journal of Perinatology (2011)
-
Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial
Journal of Cancer Research and Clinical Oncology (1997)
-
Acute inflammatory changes in subcutaneous microtumors in the ears of mice induced by intravenous CM101 (GBS toxin)
Journal of Cancer Research and Clinical Oncology (1996)
-
CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models
Journal of Cancer Research and Clinical Oncology (1995)
-
Effects of group BStreptococcus toxin on long-term survival of mice bearing transplanted Madison lung tumors
Journal of Cancer Research and Clinical Oncology (1994)